ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Non-Small-Cell Lung Carcinoma
Colorectal Cancer
Stomach Cancer
Prostatic Cancer
Esophageal Cancer
Cancer

Adenocarcinoma trials near Barcelona, CT, ESP:

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

new standard backbone in patients with resectable esophagogastric adenocarcinoma. It addresses major limitations of current treatment paradi...

Begins enrollment in 2 months
Esophagogastric Adenocarcinoma
Drug: Durvalumab

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Barcelona, Spain and 28 other locations

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Barcelona, Spain and 155 other locations

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Active, not recruiting
Gastroesophageal Cancer
Drug: Supportive care measures
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Barcelona, Spain and 167 other locations

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using...

Enrolling
Adenocarcinoma of the Pancreas
Pancreas Cancer
Device: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
HistoSonics

Barcelona, Spain

(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Drug: Sonesitatug vedotin
Drug: Nivolumab

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 229 other locations

resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....

Enrolling
Gastroesophageal Adenocarcinoma
Drug: 5-Fluorouracil (5-FU)
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 69 other locations

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Barcelona, Spain and 124 other locations

The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabin...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Atezolizumab
Drug: Gemcitabine

Phase 2

NovoCure
NovoCure

Barcelona, Spain and 14 other locations

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Barcelona, Spain and 13 other locations

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: 5-Fluorouracil
Drug: XELOX

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 43 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems